{
    "clinical_study": {
        "@rank": "57203", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "Retain 1-2 drops, bilaterally, BID"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy of Retaine\u2122 ophthalmic emulsion in treating the signs\n      and symptoms of dry eye syndrome."
        }, 
        "brief_title": "A Phase 4 Study Investigating the Efficacy of Retaine\u2122 in Managing Signs and Symptoms Associated With Dry Eye Syndrome", 
        "condition": "Keratoconjunctivitis Sicca", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be at least 18 years of age;\n\n          -  Provide written informed consent;\n\n          -  Have a reported history of dry eye;\n\n          -  Have a history of use or desire to use eye drops;\n\n        Exclusion Criteria:\n\n          -  Have any clinically significant eye findings that require therapeutic treatment,\n             and/or in the opinion of the investigator may interfere with study parameters;\n\n          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses\n             during the study;\n\n          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the\n             last 12 months;\n\n          -  Have used Restasis\u00ae within 30 days of Visit 1;\n\n          -  Be a woman who is pregnant, nursing or planning a pregnancy;\n\n          -  Be unwilling to submit a urine pregnancy test if of childbearing potential;\n\n          -  Have a known allergy and/or sensitivity to the test article or its components;\n\n          -  Have a condition or be in a situation which the investigator feels may put the\n             subject at significant risk, may confound the study results, or may interfere\n             significantly with the subject's participation in the study;\n\n          -  Be currently enrolled in an investigational drug or device study or have used an\n             investigational drug or device within 30 days of Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139033", 
            "org_study_id": "13-110-0008"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "intervention_name": "Retaine\u2122", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Carboxymethylcellulose Sodium"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Dry Eye, Dry Eye Syndrome, Retaine, KCS, Keratoconjunctivitis sicca", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Center Evaluation of Retaine\u2122 Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Tear Film Break-Up Time", 
                "safety_issue": "No", 
                "time_frame": "Day 15"
            }, 
            {
                "measure": "Ocular surface damage as measured by fluorescein staining", 
                "safety_issue": "No", 
                "time_frame": "Day 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ocusoft, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ocusoft, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}